PART I When used in this report, unless otherwise indicated, Nurix, Company, we, us and our refers to Nurix Therapeutics, Inc. and its wholly owned subsidiaries. Overview We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully artificial intelligence ...
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-01-28 | 2025-11-30 | 0001549595-26-000016 | EDGAR | 116K words |
| 2025-01-28 | 2024-11-30 | 0001549595-25-000016 | EDGAR | — |
| 2024-02-15 | 2023-11-30 | 0001549595-24-000025 | EDGAR | — |
| 2023-02-09 | 2022-11-30 | 0001549595-23-000021 | EDGAR | — |
| 2022-01-28 | 2021-11-30 | 0001564590-22-003007 | EDGAR | — |
| 2021-02-16 | 2020-11-30 | 0001564590-21-006071 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-09 | 2025-08-31 | 0001549595-25-000113 | EDGAR | 75K words |
| 2025-07-09 | 2025-05-31 | 0001549595-25-000095 | EDGAR | — |
| 2025-04-08 | 2025-02-28 | 0001549595-25-000055 | EDGAR | — |
| 2024-10-11 | 2024-08-31 | 0001549595-24-000131 | EDGAR | — |
| 2024-07-11 | 2024-05-31 | 0001549595-24-000098 | EDGAR | — |
| 2024-04-10 | 2024-02-29 | 0001549595-24-000049 | EDGAR | — |
| 2023-10-12 | 2023-08-31 | 0001549595-23-000048 | EDGAR | — |
| 2023-07-13 | 2023-05-31 | 0001549595-23-000040 | EDGAR | — |
| 2023-04-13 | 2023-02-28 | 0001549595-23-000032 | EDGAR | — |
| 2022-10-06 | 2022-08-31 | 0001564590-22-033709 | EDGAR | — |
| 2022-07-07 | 2022-05-31 | 0001564590-22-025450 | EDGAR | — |
| 2022-04-08 | 2022-02-28 | 0001564590-22-013988 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-06 | 0001193125-26-096734 | EDGAR | 1K words |
| 2026-01-28 | 0001549595-26-000013 | EDGAR | — |
| 2026-01-12 | 0001549595-26-000003 | EDGAR | — |
| 2025-12-09 | 0001549595-25-000121 | EDGAR | — |
| 2025-11-10 | 0001549595-25-000117 | EDGAR | — |
| 2025-10-22 | 0001193125-25-246964 | EDGAR | — |
| 2025-10-22 | 0001549595-25-000115 | EDGAR | — |
| 2025-10-09 | 0001549595-25-000112 | EDGAR | — |
| 2025-09-03 | 0001549595-25-000108 | EDGAR | — |
| 2025-08-22 | 0001549595-25-000105 | EDGAR | — |
113 total filings indexed. 85 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001549595 |
| Ticker | NRIX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.nurixtx.com |
| Listed | 2020-07-24 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NRIX (~200 tokens, structured JSON with cryptographic provenance)